Should You Buy BioCryst Pharmaceuticals (BCRX) Stock at Current Levels?

BioCryst Pharmaceuticals BCRX Stock News

Investors in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) have had an incredible week, and the upswing in the stock is continuing today with the stock in the green by more than 3% early on. The gains were spurred by strong sales figures and projections of more of the same, but is there any more room left … Read more

Is BioCrypst Pharmaceuticals (BCRX) Stock a Buy on ORLADEYO News?

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals (NASDAQ: BCRX) is having a strong start to the trading session this morning, up nearly 10% an hour after the open. The gains are ultimately the result of news surrounding the company’s ORLADEYO product, a treatment for hereditary angioedema that was approved in early-December 2020.  Here’s what’s happening: Stop wasting your time! Start … Read more

BioCryst Pharmaceuticals (BCRX) Stock Heads Up On Sales News

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is screaming for the top in the premarket hours this morning, and for good reason. The company announced that it has made a large sale to the United States Department of Health and Human Services, or HHS. Here’s what’s going on: Stop wasting your time! Start finding winning trades in … Read more

BCRX Stock: Here’s Why BioCryst Is Headed Up

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is headed up in the premarket hours after announcing that it plans on hosting a virtual R&D day a week from today. Here’s what’s happening: Skip to What You Want to Read BioCryst Pharmaceuticals Announces R&D Day What Is BCRX? What Analysts Think About BCRX Stock Final Thoughts BioCryst Pharmaceuticals … Read more

BCRX Stock: BioCryst Continues up on Early Access

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is adding to the gains the stock experienced yesterday after issuing a press release announcing that early access to a treatment for hereditary angioedema (HAE) has been granted in France. Here’s what’s going on: Skip to What You Want to Read BioCryst Pharmaceuticals Announces Early Access Approval ManagementCommentary What Analysts … Read more

BCRX Stock: BioCryst Climbs on Approval

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is headed up in the market this morning, and for good reason. The company announced that its ORLADEYO product has been approved for commercialization in Japan. Here’s what’s happening: Skip to What You Want to Read BioCryst Pharmaceuticals Announces ORLADEYO Approval Management Commentary Why Investors Are Excited What Analysts Think … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Falling Hard After Positive Study Results

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is having an overwhelmingly rough start in the premarket hours this morning, leaving many wondering why. The company released what it said was positive clinical data from a Phase 3 trial. However, reading between the lines shows us that things aren’t always what they seem. Today, we’ll talk about: The … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Headed Up On Fast Track Designation

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is having a great start to the trading session this morning after the company announced that its candidate has been granted Fast Track Designation by the FDA. Of course, the news excited investors, sending the stock on a run for the sky. Today, we’ll talk about: The designation; what we’re … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Gaining On Japanese Approval

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) BioCryst Pharmaceuticals is having a strong start to the trading session after announcing that one of its treatments has received regulatory approval in Japan. As a result, investor excitement ensued, leading to gains in the stock and an alert from our partners at Trade Ideas. At the moment (9:41), BCRX … Read more

Biotech Stock News (BCRX) (INCY)

BioCryst Pharmaceuticals (NASDAQ: BCRX) On February 8, 2016 shares of BioCryst Pharmaceuticals fell by more than 71% after the company had announced that it had failed a phase 2 trial. The phase 2 trial known as the OPuS-2 trial recruited a total of 108 patients with Hereditary Angiodema — HAE. HAE is a rare genetic … Read more